MX2013008850A - Composiciones y metodos para tratar enfermedades cardiovasculares. - Google Patents

Composiciones y metodos para tratar enfermedades cardiovasculares.

Info

Publication number
MX2013008850A
MX2013008850A MX2013008850A MX2013008850A MX2013008850A MX 2013008850 A MX2013008850 A MX 2013008850A MX 2013008850 A MX2013008850 A MX 2013008850A MX 2013008850 A MX2013008850 A MX 2013008850A MX 2013008850 A MX2013008850 A MX 2013008850A
Authority
MX
Mexico
Prior art keywords
methods
compositions
cardiovascular diseases
treating cardiovascular
pharmaceutical compositions
Prior art date
Application number
MX2013008850A
Other languages
English (en)
Other versions
MX364229B (es
Inventor
Brew John
Mark Bannister Robin
Alan Stoloff Gregory
Jane Dilly Suzanne
Caparros-Wanderley Wilson
Original Assignee
Biocopea Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1101937.9A external-priority patent/GB201101937D0/en
Priority claimed from GBGB1113730.4A external-priority patent/GB201113730D0/en
Priority claimed from GB1113728.8A external-priority patent/GB2487808A/en
Priority claimed from GBGB1113729.6A external-priority patent/GB201113729D0/en
Application filed by Biocopea Ltd filed Critical Biocopea Ltd
Publication of MX2013008850A publication Critical patent/MX2013008850A/es
Publication of MX364229B publication Critical patent/MX364229B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

La presente descripción describe composiciones farmacéuticas, métodos para la preparación de tales composiciones farmacéuticas y métodos y usos para el tratamiento de una enfermedad cardiovascular en un individuo utilizando tales composiciones farmacéuticas.
MX2013008850A 2011-02-04 2012-02-03 Composiciones y metodos para tratar enfermedades cardiovasculares. MX364229B (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GBGB1101937.9A GB201101937D0 (en) 2011-02-04 2011-02-04 Method of preparing a composition
GBGB1113730.4A GB201113730D0 (en) 2011-08-10 2011-08-10 Solid dosage form
GB1113728.8A GB2487808A (en) 2010-10-29 2011-08-10 Oral adjuvant or formulation comprising a lipid and an alcohol
GBGB1113729.6A GB201113729D0 (en) 2011-08-10 2011-08-10 Hyperlipidaemia
PCT/GB2011/052115 WO2012056251A1 (en) 2010-10-29 2011-10-31 Inflammatory disease
PCT/GB2012/050241 WO2012104654A1 (en) 2011-02-04 2012-02-03 Compositions and methods for treating cardiovascular diseases

Publications (2)

Publication Number Publication Date
MX2013008850A true MX2013008850A (es) 2016-09-23
MX364229B MX364229B (es) 2019-04-17

Family

ID=46602107

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2013008850A MX364229B (es) 2011-02-04 2012-02-03 Composiciones y metodos para tratar enfermedades cardiovasculares.
MX2013008851A MX346224B (es) 2011-02-04 2012-02-03 Composiciones y metodos para el tratamiento de inflamacion cronica y enfermedades inflamatorias.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2013008851A MX346224B (es) 2011-02-04 2012-02-03 Composiciones y metodos para el tratamiento de inflamacion cronica y enfermedades inflamatorias.

Country Status (11)

Country Link
EP (3) EP3494961B1 (es)
JP (3) JP2014504629A (es)
CN (2) CN103391768B (es)
AU (2) AU2012213217B2 (es)
BR (2) BR112013019734A2 (es)
CA (2) CA2826506C (es)
MX (2) MX364229B (es)
RU (3) RU2016138830A (es)
SG (3) SG192620A1 (es)
WO (2) WO2012104655A2 (es)
ZA (2) ZA201305783B (es)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104826116A (zh) * 2003-11-20 2015-08-12 诺沃挪第克公司 对于生产和用于注射装置中是最佳的含有丙二醇的肽制剂
US11224659B2 (en) 2010-10-29 2022-01-18 Infirst Healthcare Limited Solid solution compositions and use in severe pain
US9737500B2 (en) 2010-10-29 2017-08-22 Infirst Healthcare Limited Compositions and methods for treating severe pain
US9504664B2 (en) 2010-10-29 2016-11-29 Infirst Healthcare Limited Compositions and methods for treating severe pain
US9744132B2 (en) 2010-10-29 2017-08-29 Infirst Healthcare Limited Solid solution compositions and use in chronic inflammation
US9308213B2 (en) 2010-10-29 2016-04-12 Infirst Healthcare Limited Solid solution compositions and use in chronic inflammation
US11730709B2 (en) 2010-10-29 2023-08-22 Infirst Healthcare Limited Compositions and methods for treating severe pain
US8895536B2 (en) 2010-10-29 2014-11-25 Infirst Healthcare Ltd. Compositions and methods for treating chronic inflammation and inflammatory diseases
GB201018289D0 (en) * 2010-10-29 2010-12-15 Biocopea Ltd Treatment of respiratory disorders
US11202831B2 (en) 2010-10-29 2021-12-21 Infirst Healthcare Limited Solid solution compositions and use in cardiovascular disease
US9271950B2 (en) 2010-10-29 2016-03-01 Infirst Healthcare Limited Compositions for treating chronic inflammation and inflammatory diseases
US10695431B2 (en) 2010-10-29 2020-06-30 Infirst Healthcare Limited Solid solution compositions and use in cardiovascular disease
US10695432B2 (en) 2010-10-29 2020-06-30 Infirst Healthcare Limited Solid solution compositions and use in severe pain
JP6173437B2 (ja) 2012-05-07 2017-08-02 オムセラ・ファーマシューティカルズ・インコーポレイテッド スタチン及びω−３脂肪酸の組成物
US9539240B2 (en) * 2012-10-24 2017-01-10 Biocopea Limited Drug combinations and methods for reducing or maintaining cholesterol or HDL/LDL levels
RU2677346C2 (ru) * 2013-01-14 2019-01-16 ИнФерст Хэлткэр Лимитед Композиции и способы для лечения сильной боли
AU2014204733B2 (en) 2013-01-14 2016-09-08 Clinics Operations Limited Cancer drug and uses
EP2925367B1 (en) * 2013-01-14 2019-08-14 InFirst Healthcare Limited Solid solution compositions and use in chronic inflammation
CA2898017A1 (en) * 2013-02-04 2014-08-07 Infirst Healthcare Limited Compositions and methods for treating chronic inflammation and inflammatory diseases
KR101344218B1 (ko) * 2013-05-15 2013-12-20 충남대학교산학협력단 페노피브레이트를 함유하는 결핵 치료용 약학 조성물
RU2623876C2 (ru) * 2014-11-10 2017-06-29 Александр Владимирович Диковский Фармацевтическая композиция для лечения гиперлипидемии
KR101512606B1 (ko) 2014-12-11 2015-04-15 (주)이지코스 주름 및 아토피 개선과 피부 보습을 위한 화장료 조성물
CN105853405B (zh) * 2015-01-23 2019-03-08 中国科学院上海药物研究所 苯溴马隆在制备电压门控钾离子通道kcnq激动剂中的应用
EP3095465A1 (en) 2015-05-19 2016-11-23 U3 Pharma GmbH Combination of fgfr4-inhibitor and bile acid sequestrant
KR20180021735A (ko) * 2015-06-15 2018-03-05 바이탈 쎄러피스, 인코포레이티드 항염증성 반응을 유도하기 위한 조성물 및 방법
CN105294672A (zh) * 2015-12-07 2016-02-03 范秀华 一种治疗子宫内膜炎的药物组合物
CN105753826A (zh) * 2016-05-09 2016-07-13 宋晓梅 一种吉非罗齐的药物组合物及其医药用途
CN106074500A (zh) * 2016-07-08 2016-11-09 重庆医药高等专科学校 脱氢洛伐他汀在制备抗炎症性肠病药物中的应用
CA3077624A1 (en) * 2016-10-01 2018-04-05 James Smeeding Pharmaceutical compositions comprising a statin and a cannabinoid and uses thereof
WO2018129095A1 (en) * 2017-01-03 2018-07-12 Thermolife International, Llc Cinnamaldehyde compositions and methods
JP6784973B2 (ja) * 2017-03-30 2020-11-18 国立研究開発法人産業技術総合研究所 単層カーボンナノチューブ
US20210137809A1 (en) * 2017-06-14 2021-05-13 Biosolution Co., Ltd Cosmetic composition for wrinkle reduction or anti-inflammation, containing substance p
CA3068879C (en) * 2017-07-18 2022-12-13 Deyi Pharmaceutical Ltd. Use of cannabidol in treatment of pulmonary hypertension
AU2018302255A1 (en) * 2017-07-19 2020-02-06 Ironwood Pharmaceuticals, Inc. Efficacy of a gastro-retentive bile acid sequestrant dosage form
PE20211202A1 (es) 2017-08-24 2021-07-05 Novo Nordisk As Composiciones de glp-1 y sus usos
EP3677258B1 (en) * 2017-08-31 2022-02-09 Hanyi Bio-Technology Company Ltd. Uses of cannabidiol in preparation of drugs for resisting against influenza
CN109419786B (zh) * 2017-08-31 2021-04-30 汉义生物科技（北京）有限公司 大麻二酚在制备抗流感的药物中的用途
BR112020013111A2 (pt) * 2018-01-12 2020-12-01 Metimedi Pharmaceuticals Co., Ltd. métodos de tratamentos da doença de alzheimer, de esclerose múltipla, de pulpite, de doença inflamatória intestinal e de lesão medular
JP7387088B2 (ja) * 2018-06-03 2023-11-28 国立台湾大学 心筋緻密化障害の治療方法
EP3856172A4 (en) * 2018-09-28 2022-10-05 Visceral Therapeutics Inc. PHARMACEUTICALLY ACTIVE CANNABIS-BASED COMPOSITIONS AND METHODS FOR USE IN THE TREATMENT OF GASTROINTESTINAL CONDITIONS
SG11202106144VA (en) 2018-12-11 2021-07-29 Disruption Labs Inc Compositions for the delivery of therapeutic agents and methods of use and making thereof
US20220168325A1 (en) * 2019-03-25 2022-06-02 The University Of Vermont Methods to promote cerebral blood flow in the brain
CN109846885A (zh) * 2019-04-04 2019-06-07 南通大学附属医院 瑞舒伐他汀的新用途
AU2020401838A1 (en) * 2019-12-11 2022-07-21 Ambetex Pty Ltd Therapeutic compositions and methods for prevention and treatment of diastolic dysfunction
RU2749857C1 (ru) * 2019-12-23 2021-06-17 Псарева Нелли Александровна Способ борьбы со средним и наружным отитом
PE20221575A1 (es) 2020-02-18 2022-10-06 Novo Nordisk As Formulaciones farmaceuticas
JPWO2021215409A1 (es) 2020-04-20 2021-10-28
RU2745687C1 (ru) * 2020-05-19 2021-03-30 Всеволод Иванович Киселев Способ лечения эндометриоза с болевым синдромом и фармацевтическая композиция для его реализации
CN112007165B (zh) * 2020-08-27 2021-10-08 北京大学人民医院 巨噬细胞极化调节剂及其在促进血小板生成中的应用
CN112156089A (zh) * 2020-09-27 2021-01-01 天津国际生物医药联合研究院 苯溴马隆在抗结核分枝杆菌感染中的应用
WO2023058975A1 (ko) * 2021-10-07 2023-04-13 (주)이노보테라퓨틱스 벤조퓨라닐 히드록시페닐 메타논 유도체를 포함하는 hsp47 억제용 약학 조성물
WO2023244738A1 (en) * 2022-06-15 2023-12-21 The Johns Hopkins University Thiazolidinediones for the treatment of muscular dystrophies

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5154930A (en) * 1987-03-05 1992-10-13 The Liposome Company, Inc. Pharmacological agent-lipid solution preparation
US5059626A (en) * 1988-07-25 1991-10-22 Applied Analytical Industries, Inc. Liquid oral pharmaceutical compositions of non-steroidal anti-inflammatory drugs
IT1255007B (it) * 1991-07-01 1995-10-11 Altergon Sa Sale solubile dell'ibuprofen c0n n-(2-idrossietil) pirrolidina e composizioni farmaceutiche che li contengono.
US6458373B1 (en) * 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
US6063768A (en) 1997-09-04 2000-05-16 First; Eric R. Application of botulinum toxin to the management of neurogenic inflammatory disorders
US7374779B2 (en) * 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
EP1162954A1 (en) * 1999-03-31 2001-12-19 Abbott Laboratories Novel formulations comprising lipid-regulating agents
US6982281B1 (en) * 2000-11-17 2006-01-03 Lipocine Inc Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
US20030235595A1 (en) * 1999-06-30 2003-12-25 Feng-Jing Chen Oil-containing, orally administrable pharmaceutical composition for improved delivery of a therapeutic agent
CN102258457B (zh) * 2000-12-19 2015-07-01 得克萨斯系统大学董事会 非水性组合物
US20040115287A1 (en) * 2002-12-17 2004-06-17 Lipocine, Inc. Hydrophobic active agent compositions and methods
JP2005068060A (ja) * 2003-08-22 2005-03-17 Nrl Pharma Inc ラクトフェリンを含有する医薬組成物ならびに加工食品の製造法
CN100486567C (zh) * 2004-08-12 2009-05-13 山东绿叶天然药物研究开发有限公司 姜黄素乳剂及其制备方法
US20060138059A1 (en) 2004-12-28 2006-06-29 Vair Larry L Jr Corona-treated polypropylene liquid filtration media
US20070015834A1 (en) * 2005-07-18 2007-01-18 Moshe Flashner-Barak Formulations of fenofibrate containing PEG/Poloxamer
WO2008070950A1 (en) * 2006-12-13 2008-06-19 Laboratoires Mauves Inc. Pharmaceutical solution formulations for encapsulation into gelatin capsules or other dosage forms
WO2008144355A2 (en) * 2007-05-17 2008-11-27 Morton Grove Pharmaceuticals, Inc. Stable, self-microemulsifying fenofibrate compositions
US20090162442A1 (en) * 2007-09-07 2009-06-25 Shenoy Dinesh B Multi-phasic, nano-structured compositions containing a combination of a fibrate and a statin
RU2363451C2 (ru) * 2007-09-14 2009-08-10 Общество С Ограниченной Ответственностью "Технология Лекарств" Композиция для приготовления обладающей пролонгированным действием лекарственной формы и способ получения этой формы
WO2009153496A2 (fr) 2008-05-26 2009-12-23 Genfit Composés agonistes ppar, préparation et utilisations
GB2477590A (en) * 2010-02-05 2011-08-10 Biocopea Ltd A non-steroidal anti-inflammatory drug (NSAID) formulation comprising a lipid carrier
CN101926757B (zh) * 2010-09-01 2013-01-02 北京大学 一种难溶性药物的液体组合物及其制备方法

Also Published As

Publication number Publication date
JP2014507429A (ja) 2014-03-27
JP2014504629A (ja) 2014-02-24
CA2826452A1 (en) 2012-08-09
ZA201305783B (en) 2014-04-30
AU2012213217A1 (en) 2013-08-15
AU2012213218B9 (en) 2017-02-02
CN103391768A (zh) 2013-11-13
NZ613805A (en) 2016-01-29
RU2635188C2 (ru) 2017-11-09
ZA201305784B (en) 2014-04-30
AU2012213218C1 (en) 2017-04-20
EP3494961B1 (en) 2024-04-10
CN103391768B (zh) 2016-08-10
CA2826506C (en) 2017-07-25
EP2670390A2 (en) 2013-12-11
WO2012104655A2 (en) 2012-08-09
NZ711187A (en) 2016-01-29
BR112013019734A2 (pt) 2016-10-25
CN103391767B (zh) 2016-08-31
MX346224B (es) 2017-03-10
CA2826506A1 (en) 2012-08-09
BR112013019732A2 (pt) 2016-10-25
JP2016128482A (ja) 2016-07-14
MX364229B (es) 2019-04-17
EP3494961A1 (en) 2019-06-12
MX2013008851A (es) 2013-12-16
WO2012104654A1 (en) 2012-08-09
SG192620A1 (en) 2013-09-30
RU2013140775A (ru) 2015-03-10
SG10201600854SA (en) 2016-03-30
JP6273304B2 (ja) 2018-01-31
CN103391767A (zh) 2013-11-13
NZ613812A (en) 2015-08-28
BR112013019732B1 (pt) 2023-01-24
CA2826452C (en) 2016-11-22
AU2012213217B2 (en) 2017-04-20
AU2012213218B2 (en) 2017-01-12
EP2670389A1 (en) 2013-12-11
AU2012213218A1 (en) 2013-08-15
RU2016138830A (ru) 2018-12-12
WO2012104655A3 (en) 2013-03-14
RU2013140776A (ru) 2015-03-10
SG192621A1 (en) 2013-09-30

Similar Documents

Publication Publication Date Title
MX364229B (es) Composiciones y metodos para tratar enfermedades cardiovasculares.
PH12019502292A1 (en) Methods and compositions for treatment of a genetic condition
PH12014502010A1 (en) Bispecific antibodies against human tweak and human il17 and uses thereof
IL231536A (en) Indazole-3-carboxamides, pharmaceuticals containing them and their use in the treatment of diseases
PH12014501108A1 (en) Anti-il-36r antibodies
GB201106750D0 (en) Novel compounds
MD4589C1 (ro) Compoziţie farmaceutică cu conţinut de sofosbuvir şi utilizarea acesteia în tratamentul hepatitei virale C
PL2672966T3 (pl) Kompozycja farmaceutyczna, sposoby leczenia i jej zastosowania
MX349004B (es) Nuevos compuestos.
MX2015009106A (es) Composiciones de solución sólida y su uso en el tratamiento del dolor intenso.
MX2015009058A (es) Composiciones y metodos para tratar la inflamacion cronica y las enfermedades inflamatorias.
PT2729151T (pt) Composição farmacêutica, métodos de tratamento e suas utilizações
WO2012129341A3 (en) Disease detection in plants
EP2701700A4 (en) PHARMACEUTICAL THERAPY FOR INHIBITING CHEMOTHERAPY-INDUCED SIDE EFFECTS AND CORRESPONDING PHARMACEUTICAL COMPOSITIONS, DIAGNOSTICS, SCREENING METHOD AND KITS
AU2013225816A8 (en) Compositions and methods for treating Type III Gaucher Disease
MX2014010433A (es) Nueva forma cristalina de sulfato de sitagliptina.
MX357284B (es) Compuestos de quinona para tratar enfermedades mediadas por ape1.
EP4023243A3 (en) Compositions and methods for treating celiac sprue disease
GB201302343D0 (en) Pharmaceutical compositions comprising 15-OHEPA and methods for using the same
EP2785335B8 (en) Methods and pharmaceutical compositions for the treatment of darier disease
EP2742946A4 (en) PROCESS FOR THE PRODUCTION OF PYROSTEGIA VENUSTA DERIVATIVES, PYROSTEGIA VENUSTA DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF
MX2011006721A (es) Formulacion farmaceutica de fenofibrato nanonizado.
MX2014006201A (es) Formas de dosificaciones solidas de imatinib reconstituidas justo antes de usarse.
MX351765B (es) Uso de sales de 3-carboxi-n-etil-n,n-dimetilpropan-1-aminio en el tratamiento de enfermedades cardiovasculares.
TN2013000404A1 (en) Use of 3-carboxy-n-ethyl-n,n-dimethylpropan-1-aminium salts in the treatment of cardiovascular disease

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: INFIRST HEALTHCARE LIMITED

FG Grant or registration